---
title: "Pfizer (PFE) Stock Looks Stretched Even With New Pipeline Deals"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/306380591.md"
description: "Pfizer (PFE) stock appears overvalued with a P/E ratio of 38.7x, significantly above the sector average of 15.2x, despite new pipeline deals in obesity and CAR-T therapies. While bulls cite $9.7b in expected savings by 2029, bears argue current prices reflect overly optimistic execution assumptions. The Fair Ratio model suggests shares are stretched relative to present earnings power."
datetime: "2026-11-22T02:15:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/306380591.md)
  - [en](https://longbridge.com/en/news/306380591.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/306380591.md)
generator: "portal-rs"
---

# Pfizer (PFE) Stock Looks Stretched Even With New Pipeline Deals

Pfizer has been rebuilding its pipeline in areas like obesity and autoimmune disease, while the share price sits near US$27.40 after a mixed few years for investors. The key issue for you is whether that current tag is properly supported by the earnings power the business is producing today.

-   Over the past 5 years, Pfizer shareholders have seen the stock decline 33.5%, which puts the focus firmly on what the present earnings profile really justifies at this stage.
-   New deals in obesity treatments and in vivo CAR-T therapies can shift expectations for future profit streams, as they affect how much the group may need to spend on development before any earnings contribution arrives.
-   There is a second opinion on Pfizer worth weighing. See what analysts think Pfizer's shares could be worth.

The issue now is whether Pfizer's current earnings, relative to its share price, make that valuation look well supported or stretched when judged against its own Fair Ratio benchmark.

If you want to test the same earnings question that hangs over Pfizer against a wider field, scan through 40 high quality undervalued stocks to find other candidates that fit that profile.

### Has Pfizer Run Too Far on Earnings?

The P/E ratio works well for Pfizer because investors often anchor their view of large drug developers on current and near term earnings power. On this lens, Pfizer trades at about 38.7x earnings, compared with a pharmaceuticals sector average near 15.2x and a peer group around 70.8x. The stock therefore carries a clear premium to the broad industry while still sitting below the peer pack.

The Fair Ratio model, which estimates the P/E you might expect given Pfizer's margins, risk profile and scale, points to a lower figure than the current multiple, so the shares screen as overvalued on this framework. Despite recent deals in obesity and in vivo CAR-T that have sharpened attention on future pipelines, the present P/E still represents a relatively full price for today's earnings stream compared with what the model suggests. Explore the numbers behind Pfizer's P/E valuation.

### The Pfizer Narrative: What Would Justify Today's Price?

Narratives pick up where the P/E puzzle for Pfizer leaves off by spelling out which future paths for growth, profitability and earnings would need to play out for the stock to look meaningfully cheaper or richer than it appears today. Each scenario on the Community page anchors its number to a specific view on how Pfizer's growth, margins and risk profile might evolve, giving you a reference point you can revisit as fresh information comes through.

Views on Pfizer split between those who see solid execution giving the stock more room and those who think expectations already run hot.

**Bull case: 8% undervalued**

This is the analyst consensus Narrative on Simply Wall St, which blends Street forecasts into one central view.

> *"Execution on large scale productivity and manufacturing programs, now expected to deliver about US$9.7b in net savings through 2029, provides a longer runway for operating margin support…"*

Discover why this Narrative puts Pfizer at 8% undervalued.

**Bear case: 10% overvalued**

This comes from the bearish analyst Narrative on Simply Wall St, which leans on the lowest targets and assumptions.

> *"The current numbers imply Pfizer''s share price already reflects successful execution on cost savings and pipeline delivery, leaving limited room for error if any of these pillars underperform…"*

Explore why this Narrative puts Pfizer at 10% overvalued.

### One more Pfizer angle worth checking before you move on

Everything so far has focused on what Pfizer looks like today, but there is a separate question around where professional forecasts see earnings and margins a few years out, and how that lines up with the current tag. Explore where analysts expect Pfizer to be in a few years.

### Related Stocks

- [PFE.US](https://longbridge.com/en/quote/PFE.US.md)

## Related News & Research

- [Pfizer inks $2.6bn autoimmune deal with China’s Starna for CAR-T therapies](https://longbridge.com/en/news/306119677.md)
- [Pfizer Signs Licensing Deal With Starna Therapeutics for Autoimmune Disease Treatments](https://longbridge.com/en/news/305966590.md)
- [Datapharm expands SRD Search into France](https://longbridge.com/en/news/305684420.md)
- [Blackstone backs Pfizer’s obesity ambitions with $1.5bn fund](https://longbridge.com/en/news/305354338.md)
- [What Pfizer Holders Bought Into](https://longbridge.com/en/news/303132211.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**